Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33211074.
- Also identified by DOI 10.1001/jamaophthalmol.2020.4994 and PMC identifier 8005310.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In April 2019, the US Food and Drug Administration, in conjunction with 11 professional ophthalmic, vision science, and optometric societies, convened a forum on laser-based imaging. The forum brought together the Food and Drug Administration, clinicians, researchers, industry members, and other stakeholders to stimulate innovation and ensure that patients in the US are the first in the world to have access to high-quality, safe, and effective medical devices. This conference focused on the technology, clinical applications, regulatory issues, and reimbursement issues surrounding innovative ocular imaging modalities. Furthermore, the emerging role of artificial intelligence in ophthalmic imaging was reviewed. This article summarizes the presentations, discussion, and future directions.
Medical subject headings
- Eye
- Eye Diseases
- Lasers
- Ophthalmoscopes
- Ophthalmoscopy
- Technology Assessment, Biomedical
- Tomography, Optical Coherence